Adma Biologics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
ADMA Biologics achieved significant revenue and gross profit growth in 2025, driven by strong ASCENIV sales and manufacturing efficiencies, despite a reported net income decrease influenced by a prior-year tax benefit.
NASDAQ
10-K: ADMA Biologics Reports Record Net Income of $197.7 Million for 2024, Projects Continued Growth
ADMA Biologics achieves first-ever GAAP net income, reporting $197.7 million for 2024 and projecting significant revenue and earnings growth for 2025 and 2026.
NASDAQ
ADMA Biologics announces its FY2023 financial results, marking its transition to a Large Accelerated Filer and highlighting revenue growth and strategic initiatives.